Scholars Central

Conference abstractPublished 23 Sep 2013

Commercialization considerations for biosimilars

Authors: Steven Lehrer

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Biosimilars have been in the market for years driven by early products such as recombinant insulin and human growth hormone. European approval of biosimilar GCSF and erythropoietin combined with approval for Dr. Reddy?s Reditux has driven the expectation of a large market opportunity for biosimilars. Many companies have entered the space ranging from major international pharmaceutical and biopharmaceutical companies to scores of companies in emerging markets. OSG will outline the market opportunity in both developed and developing/pharmerging markets and highlight key elements required for building a success biosimilar business including; selection of therapeutic areas for development, determining the best customer segments for commercialization, developing robust clinical and regulatory plans, defining the patient experience and ensuring market access. OSG will leverage its unique insights into the decision by physicians, patients and payers to use biosimilars coupled with its team?s 20 year history with biosimilar development and commercialization.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “Steven Lehrer”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels